| Dr Hector Manuel Cabeza, MD | |
|
1001 Blythe Blvd, Medical Center Plaza Suite 200, Charlotte, NC 28203-5866 | |
| (704) 381-8840 | |
| Not Available |
| Full Name | Dr Hector Manuel Cabeza |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 1001 Blythe Blvd, Charlotte, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790942688 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | ME99977 (Florida) | Secondary |
| 208000000X | Pediatrics | 2015-02380 (North Carolina) | Primary |
| 208000000X | Pediatrics | ME99977 (Florida) | Secondary |
| Entity Name | Wake Forest University Health Sciences |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003803032 PECOS PAC ID: 4486564952 Enrollment ID: O20031105000436 |
News Archive
Spinal Modulation, Inc. announced today the completion of its $30 million Series D financing. Medtronic, Inc. joined existing investors DeNovo Ventures, ePlanet/DFJ, InCube Ventures, Johnson & Johnson Development Corporation (JJDC), Kleiner Perkins Caufield & Byers, MedVenture Associates, and Raffles Venture Partners.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.
Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.
Using the new Imaging Mass Cytometry method, researchers of UZH have investigated the pancreas of healthy organ donors and those with type 1 diabetes.
› Verified 7 days ago
| Entity Name | Carolinas Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275774333 PECOS PAC ID: 4789597477 Enrollment ID: O20031110000116 |
News Archive
Spinal Modulation, Inc. announced today the completion of its $30 million Series D financing. Medtronic, Inc. joined existing investors DeNovo Ventures, ePlanet/DFJ, InCube Ventures, Johnson & Johnson Development Corporation (JJDC), Kleiner Perkins Caufield & Byers, MedVenture Associates, and Raffles Venture Partners.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.
Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.
Using the new Imaging Mass Cytometry method, researchers of UZH have investigated the pancreas of healthy organ donors and those with type 1 diabetes.
› Verified 7 days ago
| Entity Name | Vidant Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477648731 PECOS PAC ID: 0345343893 Enrollment ID: O20070321000445 |
News Archive
Spinal Modulation, Inc. announced today the completion of its $30 million Series D financing. Medtronic, Inc. joined existing investors DeNovo Ventures, ePlanet/DFJ, InCube Ventures, Johnson & Johnson Development Corporation (JJDC), Kleiner Perkins Caufield & Byers, MedVenture Associates, and Raffles Venture Partners.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.
Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.
Using the new Imaging Mass Cytometry method, researchers of UZH have investigated the pancreas of healthy organ donors and those with type 1 diabetes.
› Verified 7 days ago
| Entity Name | Albemarle Physician Services - Sentara Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942443130 PECOS PAC ID: 8729139852 Enrollment ID: O20090630000446 |
News Archive
Spinal Modulation, Inc. announced today the completion of its $30 million Series D financing. Medtronic, Inc. joined existing investors DeNovo Ventures, ePlanet/DFJ, InCube Ventures, Johnson & Johnson Development Corporation (JJDC), Kleiner Perkins Caufield & Byers, MedVenture Associates, and Raffles Venture Partners.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.
Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.
Using the new Imaging Mass Cytometry method, researchers of UZH have investigated the pancreas of healthy organ donors and those with type 1 diabetes.
› Verified 7 days ago
| Entity Name | Outer Banks Professional Services, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891050357 PECOS PAC ID: 3173652096 Enrollment ID: O20100602000156 |
News Archive
Spinal Modulation, Inc. announced today the completion of its $30 million Series D financing. Medtronic, Inc. joined existing investors DeNovo Ventures, ePlanet/DFJ, InCube Ventures, Johnson & Johnson Development Corporation (JJDC), Kleiner Perkins Caufield & Byers, MedVenture Associates, and Raffles Venture Partners.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.
Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.
Using the new Imaging Mass Cytometry method, researchers of UZH have investigated the pancreas of healthy organ donors and those with type 1 diabetes.
› Verified 7 days ago
| Entity Name | Dlp Maria Parham Physician Practices Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215273628 PECOS PAC ID: 7719153683 Enrollment ID: O20111222000550 |
News Archive
Spinal Modulation, Inc. announced today the completion of its $30 million Series D financing. Medtronic, Inc. joined existing investors DeNovo Ventures, ePlanet/DFJ, InCube Ventures, Johnson & Johnson Development Corporation (JJDC), Kleiner Perkins Caufield & Byers, MedVenture Associates, and Raffles Venture Partners.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.
Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.
Using the new Imaging Mass Cytometry method, researchers of UZH have investigated the pancreas of healthy organ donors and those with type 1 diabetes.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hector Manuel Cabeza, MD 1001 Blythe Blvd, Charlotte, NC 28203-5866 Ph: () - | Dr Hector Manuel Cabeza, MD 1001 Blythe Blvd, Medical Center Plaza Suite 200, Charlotte, NC 28203-5866 Ph: (704) 381-8840 |
News Archive
Spinal Modulation, Inc. announced today the completion of its $30 million Series D financing. Medtronic, Inc. joined existing investors DeNovo Ventures, ePlanet/DFJ, InCube Ventures, Johnson & Johnson Development Corporation (JJDC), Kleiner Perkins Caufield & Byers, MedVenture Associates, and Raffles Venture Partners.
While new cases of colorectal cancer continue to decline in the United States, it remains the third leading cause of cancer death in the nation, according to the American Cancer Society. That is why researchers at The Cancer Institute of New Jersey are looking to add a drug known for fighting malaria to traditional chemotherapy for colorectal cancer to see if treatment can be made more effective for patients.
Veloxis Pharmaceuticals A/S today announced U.S. Food and Drug Administration approval of Envarsus XR (tacrolimus extended-release tablets) for the prophylaxis of rejection in kidney transplant patients who require or desire conversion from other twice-daily tacrolimus products to once-daily Envarsus XR.
Using the new Imaging Mass Cytometry method, researchers of UZH have investigated the pancreas of healthy organ donors and those with type 1 diabetes.
› Verified 7 days ago
Kristina Jasmin Harrell, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1350 S Kings Dr, Charlotte, NC 28207 Phone: 704-446-1422 | |
Amanda Marie Sebring, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 1001 Blythe Blvd, Medical Center Plaza Suite 200, Charlotte, NC 28203 Phone: 704-381-8840 | |
Fnu Pardeep, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 14214 Ballantyne Lake Rd, Ste 300, Charlotte, NC 28277 Phone: 704-667-2600 | |
Nicole Ludmil Ivanov, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 9908 Couloak Dr, Ste 103, Charlotte, NC 28216 Phone: 704-801-2025 | |
Dr. Kathy Garland Mohanty, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 6324 Fairview Rd Ste 350, Charlotte, NC 28210 Phone: 704-384-8600 Fax: 704-384-8610 | |
Dr. Meredith Givens Pochick, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 3129 Springbank Ln Ste 100, Charlotte, NC 28226 Phone: 704-384-5151 Fax: 704-316-2905 | |
Donald Shelton Chapman Jr., MD Pediatrics Medicare: Medicare Enrolled Practice Location: 231 S Sharon Amity Rd, Charlotte, NC 28211 Phone: 704-304-6400 |